Table 5.

Anti-proliferative activity of non-sugar analogues.

Compound (IC50, µM)	X	Y	R	SKBr3	MCF-7	LNCAP-LN3	PC3-MM2
6a41	H	CH3	H	8.88 ± 0.48a	6.93 ± 0.48a	3.21 ± 1.78b	5.36 ± 2.71b
12a41	H	CH3	COCH3	0.98 ± 0.02	1.40	1.50 ± 1.00	2.85 ± 1.66
8532	H	CH3	Noviose	7.50 ± 0.80	18.70 ± 1.44	NT	NT
73a41	H	CH3	Ms	7.33 ± 0.96	8.85 ± 0.88	19.96 ± 42.67	>100
74a41	H	CH3	Ts	> 100	> 100	0.58 ± 1.34	>100
69a	H	CH3	CONH2	3.02 ± 0.56	1.16 ± 0.08	2.61 ± 1.09	6.37 ± 4.31
70a41	H	CH3	CONHMe	2.40 ± 0.16	1.72 ± 0.16	3.75 ± 0.76	5.22 ± 2.16
71a	H	CH3	CONMe2	39.85 ± 0.48	74.35 ± 3.92	5.40 ± 6.58	>100
72a	H	CH3	PO(OMe)2	> 100	> 100	3.65 ± 5.73	>100
6b	OCH3	CH3	H	3.23 ± 1.20	11.70 ± 1.92	15.79 ± 32.60	11.23 ± 30.70
12b	OCH3	CH3	COCH3	5.72 ± 0.02	1.50 ± 0.24	1.05 ± 0.59	1.69 ± 2.05
8633	OCH3	CH3	Noviose	58.80 ± 1.04	> 100	26.57 ± 67.44	>100
73b	OCH3	CH3	Ms	> 100	> 100	>100	NT
74b	OCH3	CH3	Ts	> 100	> 100	NT	>100
69b	OCH3	CH3	CONH2	6.83 ± 0.24	6.29 ± 0.88	3.55 ± 3.44	2.62 ± 2.04
70b	OCH3	CH3	CONHMe	1.53 ± 0.16	7.78 ± 1.68	4.77 ± 8.37	3.13 ± 2.34
71b	OCH3	CH3	CONMe2	6.17 ± 1.68	34.4 ± 7.20	12.75 ± 0.32d	4.04 ± 16.68
72b	OCH3	CH3	PO(OMe)2	26.48 ± 0.80	24.22 ± 2.40	1.36 ± 2.80	31.32 ± 54.87
6c	H	OCH3	H	> 100	5.32 ± 0.08	6.18 ± 7.43	>100
12c	H	OCH3	COCH3	20.50 ± 1.28	8.62 ± 2.00	14.62 ± 23.63	19.33 ± 50.90
8733	H	OCH3	Noviose	13.90 ± 0.96	9.00 ± 4.32	0.11 ± 0.02	1.44 ± 0.32
73c	H	OCH3	Ms	>100	>100	0.87 ± 1.32	NT
74c	H	OCH3	Ts	>100	>100	0.11 ± 4.68	NT
69c	H	OCH3	CONH2	76.83 ± 1.84	5.56 ± 0.24	4.83 ± 3.87	>100
70c	H	OCH3	CONHMe	>100	6.54 ± 1.84	2.37 ± 1.44	1.68 ± 1.89
71c	H	OCH3	CONMe2	>100	>100	15.73 ± 14.09	11.57 ± 10.04
72c	H	OCH3	PO(OMe)2	18.07 ± 2.88	>100	6.58 ± 4.14	11.46 ± 6.54

^aValues represent mean ± standard deviation for at least two separate experiments performed in triplicate.

^bValues represent mean ± standard deviation from dose response curves for at least two separate experiments performed in duplicate.